New Fixed-Combination Carteolol-Netarsudil Ophthalmic Solution Shows Promise for Glaucoma
A novel preservative-free fixed-combination ophthalmic solution of carteolol hydrochloride and netarsudil dimesylate, designated FC-CN-TKN, has been developed.
Asset / Drug
Drug and asset intelligence for Glaucoma with 1 indexed intelligence signal across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
No catalysts indexed for this entity yet.
No related entities indexed yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.